Oncology Medical News about Pancreatic Neoplasms

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
Cancer Chemotherapy and Pharmacology, 10/29/09

Cohen SJ et al. – The recommended phase II dose of imexon is 875 mg/m^2 with gemcitabine 1,000 mg/m^2. DLT was acute abdominal pain and cramping. Encouraging antitumor responses support further evaluation of this combination in advanced pancreatic cancer.

<< Previous
Management of relapse after allo-SCT for AML and the role of...

Next >>
Medulloblastoma in childhood: revisiting intrathecal therapy in...

Pancreatic head resection with segmental duodenectomy for pancreatic neoplasms
Journal of Hepato-Biliary-Pancreatic Surgery, 11/09/09 Relevance Score: 68%

Risk of Pancreatic Cancer in Families With Lynch Syndrome
JAMA, 10/28/09 Relevance Score: 67%

Middle pancreatectomy for pancreatic neoplasms
Journal of Hepato-Biliary-Pancreatic Surgery, 11/16/09 Relevance Score: 66%

Duodenum-preserving total pancreatectomy for pancreatic neoplasms
Journal of Hepato-Biliary-Pancreatic Surgery, 11/03/09 Relevance Score: 66%

Isolated pancreatic hypoplasia: A rare but significant radiological finding
Saudi Journal of Gastroenterology, 10/05/09 Relevance Score: 66%